Previous 10 | Next 10 |
home / stock / allo / allo articles
U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) rose sharply ...
SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company...
Allogene Therapeutics Inc (NASDAQ: ALLO) announced deprioritizing the currently enrolling third line Phase 2 ALPHA2 and EXPAND trials of cema-...
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday. Shares of Franklin Covey Co. (NYSE: FC...
Four Core Programs Leverage Unique Attributes in Product Development and Trial Design to Demonstrate the Unmatched Potential of an Allogeneic CAR...
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company...
Shares of Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) rose sharply during Tuesday’s session after the company released topline data from...
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results. AAR reported ...
U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of Karuna Therapeutics, Inc. (NASDAQ: KRTX) rose sh...
News, Short Squeeze, Breakout and More Instantly...
Allogene Therapeutics Inc. Company Name:
ALLO Stock Symbol:
NASDAQ Market:
Allogene Therapeutics Inc. Website:
Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute; Astera Cancer Care, Part of the OneOncology Network; and Norton Cancer Institute ALPHA3 Will be the First Pivotal Trial to Offer CAR T as Part of First Line (...
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced it will participate in th...
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the pricing of an underwr...